Effects of physostigmine on scopolamine-induced changes in quantitative electroencephalogram and cognitive performance

Human Psychopharmacology

Volumn 13, Issue 3, 1998, Pages 199-210

  Ebert, Ulrike ^a   Oertel, Reinhard ^a   Wesnes, Keith A ^b   Kirch, Wilhelm ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b Cognitive Drug Research Ltd ^*  (United Kingdom)

Author keywords

Cognitive performance; Electroencephalogram; Physostigmine; Scopolamine

Indexed keywords

PHYSOSTIGMINE SALICYLATE; PLACEBO; SCOPOLAMINE;

AGING; ALZHEIMER DISEASE; ARTICLE; CHOLINERGIC TRANSMISSION; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DELTA RHYTHM; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; DRUG MECHANISM; DRUG MIXTURE; ELECTROENCEPHALOGRAM; HUMAN; HUMAN EXPERIMENT; LEARNING; MALE; MEMORY; NORMAL HUMAN; PRIORITY JOURNAL; PSYCHOMETRY; RANDOMIZED CONTROLLED TRIAL; RECALL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031955434     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1077(199804)13:3<199::AID-HUP974>3.0.CO;2-3     Document Type: Article

References (34)

1. Asthana, S., Greig, N. H., Hegedus, L., Holloway, H. H., Raffaele, K. C., Schapiro, M. B. and Soncrant, T. T. (1995). Clinical pharmacokinetics of physostigmine in patients with Alzheimer's disease. Clinical Pharmacology and Therapeutics, 58, 299-309.
2. Bartus, R. (1978). Evidence for a direct cholinergic involvement in the scopolamine-induced amnesia in monkeys: effects of concurrent administration of physostigmine and methylphenidate with scopolamine. Pharmacology, Biochemistry and Behavior, 9, 833-836.
3. Bartus, R. (1979). Physostigmine and recent memory: effects in young and aged non-human primates. Science, 206, 1087-1089.
4. Bartus, R. T., Dean, R. L. and Beer, B. (1980). Memory deficits in aged cebus monkeys and facilitation with central cholinomimetics. Neurobiology of Aging, 1, 145-152.
5. Bartus, R. T., Dean, R. L., Beer, B. and Lippa, A. S. (1982). The cholinergic hypothesis of geriatric memory dysfunction. Science, 217, 408-417.
6. Bond, A. and Lader, M. (1974). The use of analogue scales in rating subjective feelings. British Journal of Medical Psychology, 80, 1-46.
7. Buzsaki, G., Bickford, R. G., Ponomareff, G., Thal, L. J., Mandel, R and Gage, F. H. (1988). Nucleus basalis and thalamic control of the neocortical activity in the freely moving rat. Journal of the Neurological Science. 8, 4007-4026.
8. Davies, P. and Maloney, A. J. (1976). Selective loss of cholinergic neurons in Alzheimer's disease. Lancet, ii, 1403-1405.
9. Davis, K. L. and Mohs, R. C. (1982). Enhancement of memory processes in Alzheimer's disease with multiple-dose intravenous physostigmine. American Journal of Psychiatry, 139, 1421-1424.
10. Deutsch, J. A. (1971). The cholinergic synapse and the site of memory. Science, 174, 788-794.
11. Drachmann, D. A., Leavitt, J. and Chicago, M. A. (1974). Human memory and the cholinergic system. Archives of Neurology, 30, 113-121.
12. Emilien, G. (1989). Effect of drugs acting on monoaminergic and cholinergic systems on quantified EEG of rats. Neuropsychobiology, 21, 205-215.
13. 11C]scopolamine and positron emission tomography. Journal of Cerebral Blood Flow and Metabolism, 12, 147-154.
14. Ghoneim, M. M. and Mewaldt, S. P. (1977). Studies on human memory: the interactions of diazepam, scopolamine, and physostigmine. Psychopharmacology, 52, 1-6.
15. Gustafson, L. (1993). Physostigmine and tetrahydroaminoacridine treatment of Alzheimer's disease. Acta Neurologica Scandinavica, 149, 39-41.
16. Gustafson, L., Edvinsson, L., Dahlgren, N., Hagberg, B., Risberg, J., Rosen, I. and Fernö, H. (1987). Intravenous physostigmine treatment of Alzheimer's disease evaluated by psychometric testing, regional cerebral blood flow (rCBF) measurement, and EEG. Psychopharmacology, 93, 31-35.
17. Herrmann, W. M., Kubicki, St., Kunkel, H., Kugler, J., Lehmann, D., Maurer, K., Rappelsberger, P. and Scheuler, W. (1989). Empfehlungen der Deutschen EEG-gesellschaft für das mapping von EEG-parametern (EEG- und EP-mapping). Zeitschrift für Elektroenzephalographie und Elektromyographie und verwandte Gebiete, 20, 125-132.
18. Iznak, A. F., Chayanov, N. V., Gavrilova, S. I., Seleznyova, N. D., Kolykhalov, I. V., Mikhailova, N. M. and Kalyn, Ya. B. (1992). EEG mapping in dementia of the Alzheimer type. Dementia, 3, 44-46.
19. Jasper, H. H. (1958). The ten-twenty electrode system of the International Federation. Electroencephalography and Clinical Neurophysioology, 10, 371-375.
20. Murray, C. L. and Fibiger, H. C. (1986). Pilocarpine and physostigmine attenuate spatial memory impairments produced by lesions of the nucleus basalis magnocellularis. Behavioral Neuroscience, 100, 23.
21. Neufeld, M. Y., Rabey, M. J., Parmet, Y., Sifris, P., Treves, T. A. and Korczyn, A. D. (1994). Effects of a single intravenous dose of scopolamine on the quantitative EEG in Alzheimer's patients and age-matched controls. Electroencephalography and Clinical Neurophysiology, 91, 407-412.
22. Preston, G. C., Ward, C., Lines, C. R., Poppleton, P., Haigh, J. R. M. and Traub, M. (1989). Scopolamine and benzodiazepine model in dementia: cross-reversals by Ro 15-1788 and physostigmine. Psychopharmacology, 98, 487-494.
23. Sannita, W. G., Maggi, L. and Rosadini, G. (1987). Effects of scopolamine (0·25-0·75 mg i.m.) on the quantitative EEG and the neuropsychological status of healthy volunteers. Neuropsychobiology, 17, 199-205.
24. Schellenberg, R., Milch, W., Schwarz, A., Schober, F. and Dimpfel, W. (1994). Quantitative EEG and BPRS data following haldol-decanoate - administration in schizophrenics. International Clinical Psychopharmacology, 9, 17-24.
25. Schober, F. and Dimpfel, W. (1992). Relation between psychometric tests and quantitative topographic EEG in pharmacology. International Journal of Clinical Pharmacology, Therapy and Toxicology, 30, 428-430.
26. Sloan, E. P., Fenton, G. W. and Standage, K. P. (1992). Anticholinergic drug effects on quantitative electroencephalogram, visual evoked potential, and verbal memory. Biological Psychiatry, 31, 600-606.
27. Thal, L. J., Fuld, P. A., Masur, D. M. and Sharpless, N. S. (1983). Oral physostigmine and lecithin improve memory in Alzheimer's disease. Annals of Neurology, 13, 491-496.
28. Weingartner, H. (1985). Models of memory dysfunction. Annals of New York Academy of Science, 444, 359-369.
29. Wennberg, A. and Widen, L. (1974). EEG och elektroneurografi vid organisk demens. Läkartidningen, 71, 1282-1284.
30. Wesnes, K. (1988). An investigation of the range of cognitive impairments induced by scopolamine-0·6 mg s.c. Human Psychopharmacology, 3, 27-41.
31. Wesnes, K. A., Simpson, P. M., White, L., Pinker, S., Jertz, G., Murphy, M. and Siegfried, K. (1991). Cholinesterase inhibition in the scopolamine model of dementia. Annals of New York Academy of Science, 640, 268-271.
32. White, P., Hiley, C., Goodhardt, M., Carrasco, L. H., Keet, J. P., Williams, I. E. and Bowen, D. M. (1977). Neocortical cholinergic neurons in elderly people. Lancet, 1, 668-670.
33. Whitehouse, P. J., Price, D. L., Clark, A. W., Coyle, J. T. and DeLong, M. R. (1981). Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Annals of Neurology, 10, 122-126.
34. Yamamoto, J. (1988). Roles of cholinergic, dopaminergic, moradrenergic, serotoninergic and GABAergic systems in changes of the EEG power spectra and behavioral states in rabbits. Japanese Journal of Pharmacology, 47, 123-134.